Improvements in the clinical signs of Parkinson’s disease using photobiomodulation: a 3-year follow-up case series

Article Sidebar

5-Apr-3690.pdf
Published Apr 4, 2023
DOI: https://doi.org/10.18103/mra.v11i3.3690

Downloads

Download data is not yet available.

Main Article Content

Ann Liebert, PhD
Department of Medicine and Health Sciences, University of Sydney, Camperdown, NSW, 2006, Australia; Governance and Research Department, Sydney Adventist Hospital, 185 Fox Valley Rd, Wahroonga, NSW, 2076, Australia; NICM Research Institute, Western Sydney University, Westmead Campus, 58-160 Hawkesbury Rd, Westmead, NSW, 2145, Australia
Brian Bicknell, PhD
NICM Research Institute, Western Sydney University, Westmead Campus, 58-160 Hawkesbury Rd, Westmead, NSW, 2145, Australia
E-Liisa Laakso, PhD
Mater Research Institute, University of Queensland, Raymond Terrace, Level 3 Aubigny Place, South Brisbane, QLD, 4101, Australia; Menzies Health Institute Queensland, Griffith University, Gold Coast Campus, QLD, 4222, Australia
Sharon Tilley, PhD
Lymphoedema And Laser Therapy, Stepney, SA, Australia
Vincent Pang, PhD
NICM Research Institute, Western Sydney University, Westmead Campus, 58-160 Hawkesbury Rd, Westmead, NSW, 2145, Australia
Gillian Heller, PhD
NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, 2006, Australia; Department of Mathematics and Statistics, Macquarie University, Balaclava Rd, Macquarie Park, NSW, 2109, Australia
John Mitrofanis, PhD
Université Grenoble Alpes, Fonds de dotation (FDD) Clinatec, rue des Martyrs 38054 Grenoble, France; Institute of Ophthalmology, University College London, Gower Street, London, WC1E 6BT, United Kingdom
Geoffrey Herkes, PhD
Governance and Research Department, Sydney Adventist Hospital, 185 Fox Valley Rd, Wahroonga, NSW, 2076, Australia; Neurologist, Sydney Adventist Hospital, 185 Fox Valley Rd, Wahroonga, NSW, 2076, Australia
Hosen Kiat, MBBS, DMedSc
NICM Research Institute, Western Sydney University, Westmead Campus, 58-160 Hawkesbury Rd, Westmead, NSW, 2145, Australia; Faculty of Medicine, Health and Human Sciences, Macquarie University, Balaclava Rd, Macquarie Park, NSW, 2109, Australia; Cardiac Health Institute, 16-18 Bridge St, Epping, NSW, 2121, Sydney, Australia

Abstract

Parkinson’s disease is a progressive neurodegenerative disease with clinical signs and symptoms that deteriorate over time. We have previously demonstrated that a combination of transcranial and remote photobiomodulation treatment has the potential to improve some clinical signs of Parkinson’s disease for up to one-year. The objective of the current study was to assess the effectiveness of continued home photobiomodulation treatment over a three-year period. Eight of the original twelve participants returned for reassessment at 2 years and six at 3 years. Participants were assessed for mobility, fine motor control, balance, and cognition. Median values for mobility and cognition continued to improve to 2 years and slightly declined to 3-years although not to pre-treatment levels. Individual participants typically improved in some outcome measures to 2-years and some participants continued to improve to 3-years. Cognition was the most sustained outcome improvement and static balance the least. Two participants who discontinued treatment after 1 year showed a decline in outcome measures. No negative side-effects of the treatment were reported. In conclusion, results suggested that at-home photobiomodulation treatment was effective to maintain improvements in clinical signs and symptoms of Parkinson’s disease for as long as treatment continued. The results of this study warrant a larger prospective randomized trial.

Keywords: Parkinson’s disease, photobiomodulation, motor symptoms, cognition, balance

Article Details

How to Cite
LIEBERT, Ann et al. Improvements in the clinical signs of Parkinson’s disease using photobiomodulation: a 3-year follow-up case series. Medical Research Archives, [S.l.], v. 11, n. 3, apr. 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3690>. Date accessed: 19 apr. 2024. doi: https://doi.org/10.18103/mra.v11i3.3690.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 11 No 3 (2023): March issue, Volume 11, Issue 3
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Erro R, Brigo F, Tamburin S, Zamboni M, Antonini A, Tinazzi M. Nutritional habits, risk, and progression of Parkinson disease. Journal of neurology. 2018;265(1):12-23. doi: https://doi.org/10.1007/s00415-017-8639-0

2. Lang AE, Eberly S, Goetz CG, et al. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Movement Disorders. 2013;28(14):1980-1986. doi: https://doi.org/10.1002/mds.25671

3. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. Journal of Neurology, Neurosurgery & Psychiatry. 2011;82(10):1112-1118. doi: http://dx.doi.org/10.1136/jnnp.2011.240366

4. Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort. Movement Disorders Clinical Practice. 2018/01/01 2018;5(1):47-53. doi: https://doi.org/10.1002/mdc3.12553

5. Picillo M, LaFontant D-E, Bressman S, et al. Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease. Journal of Parkinson's Disease. 2022;12:421-436. doi:10.3233/JPD-212892

6. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for non-motor symptoms of Parkinson's disease—an evidence‐based medicine review. Movement Disorders. 2019;34(2):180-198. doi: https://doi.org/10.1002/mds.27602

7. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. Aug 2018;33(8):1248-1266. doi: 10.1002/mds.27372

8. Lewis MM, Harkins E, Lee EY, et al. Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements. J Parkinsons Dis. 2020;10(3):1075-1085. doi: 10.3233/jpd-201932

9. Salehpour F, Hamblin MR. Photobiomodulation for Parkinson’s disease in animal models: A systematic review. Biomolecules. 2020;10(4):610. doi: https://doi.org/10.3390/biom10040610

10. Tsai C. Progress of Photobiomodulation for Parkinson’s Disease. SOJ Complement Emerg Med. 2022;2(1):1-7. doi: https://doi.org/10.53902/SOJCEM.2022.02.000514

11. Liebert A, Bicknell B, Laakso EL, et al. Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study. BMC Neurology. 2021/07/02 2021;21(1):256. doi: 10.1186/s12883-021-02248-y

12. Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. Journal of Neurology. 2019/08/01 2019;266(8):1927-1936. doi:10.1007/s00415-019-09348-3

13. Bartl M, Dakna M, Schade S, et al. Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale in Two Independent Cohorts with Early Parkinson’s Disease. Journal of Parkinson's Disease. 2022;12:437-452.
doi: 10.3233/JPD-212860

14. Chahine LM, Siderowf A, Barnes J, et al. Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures. Journal of Parkinson's Disease. 2019;9:665-679. doi: 10.3233/JPD-181518

15. Mollenhauer B, Zimmermann J, Sixel-Döring F, et al. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Movement Disorders. 2019;34(1): 67-77. doi: https://doi.org/10.1002/mds.27492

16. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson's disease. A prospective study. Movement disorders. 2007;22(7):938-945. doi:https://doi.org/10.1002/mds.21429

17. Helmy A, Hamid E, Salama M, Gaber A, El-Belkimy M, Shalash A. Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical. The Egyptian journal of neurology, psychiatry and neurosurgery. 2022;58(1):1-10. doi: https://doi.org/10.1186/s41983-022-00445-1

18. Yoo JE, Jang W, Shin DW, et al. Timed up and go test and the risk of Parkinson's disease: a nation‐wide retrospective cohort study. Movement Disorders. 2020;35(7):1263-1267. doi: https://doi.org/10.1002/mds.28055

19. Steffen T, Seney M. Test-retest reliability and minimal detectable change on balance and ambulation tests, the 36-item short-form health survey, and the unified Parkinson disease rating scale in people with parkinsonism. Physical therapy. 2008; 88(6): 733-746. doi: https://doi.org/10.2522/ptj.20070214

20. Hass CJ, Bishop M, Moscovich M, et al. Defining the clinically meaningful difference in gait speed in persons with Parkinson disease. J Neurol Phys Ther. Oct 2014;38(4):233-8. doi: 10.1097/npt.0000000000000055

21. Lidstone SC. Great Expectations: The Placebo Effect in Parkinson’s Disease. In: Benedetti F, Enck P, Frisaldi E, Schedlowski M, eds. Placebo. Springer Berlin Heidelberg; 2014:139-147.

22. Lidstone SC, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Archives of general psychiatry. 2010;67(8):857 -865. doi:10.1001/archgenpsychiatry.2010.88

23. Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. Movement Disorders. 2018;33(8):1213-1227. doi: https://doi.org/10.1002/mds.27438

24. Goetz CG, Leurgans S, Raman R. Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Movement Disorders. 2002;17(2):283-288. doi: https://doi.org/10.1002/mds.10024

25. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology. 2000;54(3):710-710. doi: 10.1212/wnl.54.3.710

26. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Movement Disorders. 2008;23(5):690-699. doi: 10.1002/mds.21894

27. Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson’s disease: a systematic review. Parkinson’s disease. 2013;2013. doi: https://doi.org/10.1155/2013/906274

28. Bloem BR, Grimbergen YAM, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. Journal of Neurology. 2001/11/01 2001;248 (11):950-958. doi: 10.1007/s004150170047

29. Creaby MW, Cole MH. Gait characteristics and falls in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism & Related Disorders. 2018/12/01/ 2018;57:1-8. doi: https://doi.org/10.1016/j.parkreldis.2018.07.008

30. Port RJ, Rumsby M, Brown G, Harrison IF, Amjad A, Bale CJ. People with Parkinson’s Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration? Journal of Parkinson's Disease. 2021;11:715-724. doi: 10.3233/JPD-202346

31. Morris S, Morris ME, Iansek R. Reliability of measurements obtained with the Timed “Up & Go” test in people with Parkinson disease. Physical therapy. 2001;81(2):810-818. doi: https://doi.org/10.1093/ptj/81.2.810

32. Lang JT, Kassan TO, Devaney LL, Colon-Semenza C, Joseph MF. Test-Retest Reliability and Minimal Detectable Change for the 10-Meter Walk Test in Older Adults With Parkinson's disease. Journal of Geriatric Physical Therapy. 2016;39(4). doi: https://doi.org/10.1519/JPT.0000000000000068

33. Sebastia-Amat S, Tortosa-Martínez J, García-Jaén M, Pueo B. Within-subject variation in the cognitive timed up and go test as an explanatory variable in fall risk in patients with parkinson's disease. J Rehabil Med. Oct 26 2021;53(10 (October)):jrm00234. doi: 10.2340/16501977-2874

34. Çekok K, Kahraman T, Duran G, et al. Timed Up and Go Test With a Cognitive Task: Correlations With Neuropsychological Measures in People With Parkinson’s Disease. Cureus. 2020;12(9). doi: DOI: 10.7759/cureus.10604

35. Erro R, Picillo M, Vitale C, et al. The non‐motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4‐year longitudinal study. European Journal of Neurology. 2016; 23(11):1673-1679. doi: https://doi.org/10.1111/ene.13106

36. Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life. Journal of Neurology. 2012/12/01 2012;259(12):2621-2631. doi: 10.1007/s00415-012-6557-8

37. Biundo R, Fiorenzato E, Antonini A. Chapter Eleven - Non-motor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions. In: Chaudhuri KR, Titova N, eds. International Review of Neurobiology. Academic Press; 2017:389-415.

38. Liebert A. Emerging applications of photobiomodulation therapy: the interaction between metabolomics and the microbiome. Photomedicine and Laser Surgery. 2018; 36(10):515-517. https://doi.org/10.1089/pho.2018.4527

39. Brown EG, Chahine LM, Goldman SM, et al. The Effect of the COVID-19 Pandemic on People with Parkinson's Disease. J Parkinsons Dis. 2020;10(4):1365-1377. doi: 10.3233/jpd-202249

40. Liebert A, Bicknell B, Laakso E-L, et al. Remote Photobiomodulation Treatment for the Clinical Signs of Parkinson's Disease: A Case Series Conducted During COVID-19. Photobiomodulation, photomedicine, and laser surgery. 2022;40(2):112-122. https://doi.org/10.1089/photob.2021.0056

41. Church FC. Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease. Biomolecules. 2021;11(4):612